Follow The Filings

ORMP Oramed Pharmaceuticals

Oramed Pharmaceuticals earnings company data as of 7:04 PM ET 11/19

  • 0 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS 0.43 0.43 In line 0.0%
Rev — $6.6M —

Insider trades

Open-market buys and sales by ORMP's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ORMP insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $1.2M sold by 2 insiders under 10b5-1 plans
  1. Avraham Gabay CFO
    Planned sale
    $90K 20,000 shares at $4.51 2.3% of stake
    Traded Oct 1 Filed Oct 2
  2. Joshua Hexter COO
    Planned sale
    $135K 30,000 shares at $4.51 2.2% of stake
    Traded Oct 1 Filed Oct 2
  3. Joshua Hexter COO
    Planned sale
    $611K 137,000 shares at $4.46 12% of stake
    Traded Jul 1 Filed Jul 2
  4. Avraham Gabay CFO
    Planned sale
    $331K 73,360 shares at $4.51 9.8% of stake
    Traded Jul 1 Filed Jul 2

Also filed in the last 12 months, not counted as buying or selling: 43 stock grants, 5 option exercises, 2 share withholdings for taxes, and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
8-K 8.01
SCHEDULE 13G/A —
10-Q QUARTERLY REPORT
8-K 5.07
SCHEDULE 13G/A —
10-Q QUARTERLY REPORT
DEF 14A PROXY STATEMENT
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
SCHEDULE 13D/A —
8-K 5.03,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13D/A —
10-Q QUARTERLY REPORT
SCHEDULE 13G —
SCHEDULE 13D —
8-K 1.01,2.01
10-K ANNUAL REPORT

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf